CGT
HEALTHCARE



YOUR CELL & GENE THERAPY JOURNEY STARTS HERE

A guide to cell collection, treatment evaluation, and potential therapy pathways.

WHAT YOU'LL FIND INSIDE

This guide introduces cell and gene therapies, explains the collection experience, and outlines how potential treatment pathways are evaluated. It also explains where you'll review your options and decide whether to proceed.

UNDERSTANDING CELL & GENE THERAPY

A simple explanation of cell therapy and how a patient's own cells may be used.

THE APHERESIS PROCESS

What apheresis is and what happens before, during, and after collection.

CGT HEALTHCARE ROLE

How our team supports patients and coordinates this stage of care.

YOUR PERSONALIZED PROPOSAL

Information prepared specifically for you and your care plan.

This guide provides general educational information. Your healthcare provider will give you instructions specific to your treatment and care.



CAR-T Cell and Gene therapy is the future of cancer treatment, and as physicians, we must do everything in our power to increase patient access to these groundbreaking therapies" -
Andrew Branagan, MD, PhD Medical Director

UNDERSTANDING CELL AND GENE THERAPIES

Cells are the building blocks of the body. Genes are the instructions inside cells that tell them how to function. Cell and gene therapies use cells, genetic material, or a combination of both to address disease in new and highly targeted ways.

CELL THERAPY

Cell therapy uses living cells to help repair, replace, restore, or support a function in the body. The cells may come from the patient or from a donor. Depending on the therapy, they may be collected, selected, grown, or otherwise prepared before being administered to the patient.

GENE THERAPY

Gene therapy works by changing genetic material within cells to help treat disease. This may involve adding a working gene, turning off a gene that is causing a problem, or repairing or editing a gene. These changes may take place inside the body or in cells collected and modified outside the body.

WHEN CELL AND GENE THERAPY WORK TOGETHER

Some treatments combine both approaches. A patient's cells may be collected, genetically modified in a laboratory, and then returned to the patient. CAR-T cell therapy is one example of a gene-modified cell therapy.

Understanding these therapies is a starting point. Your care team will evaluate which options may be appropriate for your condition and what would be required to move forward.



FDA-APPROVED CELL & GENE THERAPIES

Cell and gene therapies are already being used to treat certain cancers, blood and immune disorders, inherited conditions, neurologic diseases, and other serious conditions.

CAR-T AND IMMUNE CELL THERAPIES

Abecma (idecabtagene vicleucel)

AUCATZYL obecabtagene autoleucel

Breyanzi

CARVYKTI (ciltacabtagene autoleucel)

KYMRIAH (tisagenlecleucel) Suspension for IV infusion

TECARTUS (brexucabtagene autoleucel) Suspension for IV infusion

YESCARTA (axicabtagene ciloleucel) Suspension for IV infusion

GENE-MODIFIED CELL THERAPIES

casgevy (exagamglogene autotemcel) suspension for IV infusion

lenmeldy (atidarsagene autotemcel)

lyfgenia (lovotibeglogene autotemcel) suspension for IV infusion

zynteglo (betibeglogene autotemcel) suspension for IV infusion

GENE THERAPIES DELIVERED IN THE BODY

BEQVEZ fidanacogene elaparvovec-dzkt Suspension for intravenous infusion 1×10^{13} vg/mL

Elevidys delandistrogene moxeparvovec-rokl suspension for intravenous infusion

HEMGENIX etranacogene dezaparvovec-drlb

LUXTURNA voretigene neparvovec-rzyl for subretinal injection

ROCTAVIAN (valoctocogene roxaparvovec-rvox) Suspension for intravenous infusion

These are selected examples, not a complete list. FDA approvals and product availability continue to change. Scan the QR code to view the FDA's current list of approved cellular and gene therapy products.

AN FDA-APPROVED THERAPY MAY NOT BE APPROPRIATE OR AVAILABLE FOR EVERY PATIENT. YOUR HEALTHCARE TEAM CAN HELP YOU UNDERSTAND WHICH OPTIONS MAY APPLY TO YOUR DIAGNOSIS AND TREATMENT PLAN.

WHAT IS CAR-T THERAPY?

Chimeric **A**ntigen **R**eceptor **T** cell **Therapy**





Reprogramming immune cells to recognize and target disease

CAR-T cell therapy is a type of cell and gene therapy that uses T cells, an important part of the body's immune system.

T cells are collected from the patient's blood via apheresis and sent to a specialized laboratory. There, they are genetically modified to produce a chimeric antigen receptor, or CAR. This receptor helps the T cells recognize a specific protein, called an antigen, on the surface of targeted cells.

The modified CAR T cells are multiplied and returned to the patient through an infusion. Once inside the body, they can locate cells carrying the target antigen and activate an immune response against them.

CAR-T therapies are currently approved for certain cancers and are also being studied for other conditions, including autoimmune diseases and solid tumors.

CAR-T is one potential therapy pathway. Your evaluation will help determine whether it or another approach may be appropriate for you.



HOW CAR-T CELL THERAPY WORKS

A general overview of the CAR-T treatment process

CELL COLLECTION

T-cells are collected from the patient's blood through a process called apheresis.

CELL ENGINEERING

In a specialized laboratory, the T cells are genetically modified to recognize a specific target.

CELL EXPANSION

The modified CAR T cells are multiplied and tested before being prepared for the patient.

CELL THERAPY

The patient may receive treatment to prepare the body before the CAR T cells are returned through an infusion.

TARGETING & MONITORING

The CAR T cells seek out cells carrying the target antigen. The patient is closely monitored during recovery and follow-up.

This process applies when CAR-T is the selected treatment. Eligibility, preparation, and timing depend on the specific therapy and your medical needs.

UNDERSTANDING APHERESIS

Apheresis is a process that uses a specialized machine to separate and collect a specific part of the blood while returning the remaining components to your body.

For many cell therapies, a type of apheresis called leukapheresis is used to collect white blood cells. These include T cells, the immune cells used to create CAR-T cell therapies.

HOW THE PROCESS WORKS

BLOOD IS DRAWN USING APHERESIS

Blood flows from a vein into the apheresis machine.

CELLS ARE SEPARATED

The machine separates and collects the targeted blood cells.

BLOOD IS RETURNED

The remaining blood components are returned to your body.

WHY ARE CELLS COLLECTED?

Depending on your care plan, collected cells may be tested, processed, cryopreserved for future use, or sent to a specialized facility for manufacturing.

Apheresis collects cells—it is not the therapy itself. What happens next will depend on your individual care plan and the pathway available to you.

YOUR APHERESIS APPOINTMENT

How to Prepare and What to Expect

Your CGT Global care team will coordinate your medical review, required documentation, testing, scheduling, and collection details. Because every patient is different, always follow the specific instructions provided by your care team.

BEFORE YOUR APPOINTMENT

COMPLETE YOUR PRE-COLLECTION STEPS

Submit requested forms, medical records, laboratory results, and other documentation before your appointment. A CGT Global physician will review your relevant medical information before you proceed.

REVIEW YOUR MEDICATIONS

Provide a complete list of prescriptions, over-the-counter medications, vitamins, supplements, and allergies. Do not stop or change any medication unless your care team instructs you to do so.

EAT AND DRINK

Unless instructed otherwise, eat a balanced meal and drink plenty of fluids before your collection. Your care team may also recommend calcium-rich foods before and during the appointment.

DRESS COMFORTABLY

Wear loose, comfortable clothing with sleeves that provide easy access to your arms.

THE DAY OF YOUR COLLECTION

CHECK-IN AND ASSESSMENT

Your CGT Global care team will review your information, answer questions, check your vital signs, and assess your veins.

GETTING CONNECTED

Most collections use an IV in each arm—one to draw blood and one to return it. If your arm veins cannot support the procedure, your care team will discuss whether another type of access is needed.

CELL COLLECTION

Blood passes through a specialized apheresis machine that separates and collects the targeted cells. The remaining blood components are continuously returned to your body.

COMFORT AND MONITORING

You will rest in a reclining chair while trained clinical staff monitor you throughout the procedure. If IVs are placed in both arms, you may need to keep your arms relatively still.

PLAN FOR APPROXIMATELY 4–6 HOURS

The length of your appointment may vary based on your individual collection plan and how your body responds.

AFTER YOUR COLLECTION

WHAT TO EXPECT AS YOU RECOVER

Once your collection is complete, the clinical team will disconnect you from the apheresis machine and provide instructions based on your individual procedure.

BEFORE YOU LEAVE

Your care team will:

- Remove your IVs or disconnect your collection line
- Apply pressure and bandages to the access sites
- Check how you are feeling and monitor you as needed
- Review your discharge and follow-up instructions

RECOVERING AT HOME

It is common to feel tired or notice mild tenderness or bruising where the IVs were placed.

- Keep your bandages in place for the amount of time your care team recommends
- Drink fluids and eat a balanced meal
- Take it easy and resume normal activities as directed
- Follow any additional instructions for caring for your IV or catheter sites

SUPPORT AFTER YOUR COLLECTION

Before your apheresis procedure, your care team will review potential side effects, explain what to watch for, and answer any questions you may have.
After your collection, support is available 24 hours a day. Contact your care team if you experience any concerning symptoms or have questions about your recovery.

CGT GLOBAL
877-900-7836

AFTER HOURS LINE
888-365-5544

For a medical emergency, call 911 or seek immediate medical attention.

Your care team will explain what happens next and contact you if additional appointments, testing, or collections are needed.

WHAT HAPPENS TO YOUR CELLS NEXT?

FROM COLLECTION TO POTENTIAL FUTURE USE

What happens after apheresis depends on your individual care plan. Your collected cells may be prepared, evaluated, cryopreserved, stored, or transferred to another facility.

PREPARATION

Your collected cells are carefully handled and prepared according to the requirements of your individual care plan.

CRYOPRESERVATION

The cells may be gradually cooled and frozen at very low temperatures. This process, called cryopreservation, is designed to maintain the cells during long-term storage.

SECURE STORAGE

Cryopreserved cells may be stored in a controlled facility until they are needed or further instructions are provided.

RELEASE OR TRANSFER

If a potential treatment pathway is identified, your healthcare team and the receiving facility will review whether your collected cells meet its requirements. Any release or transfer for additional processing or manufacturing will require appropriate authorization and coordination.

LOOKING AHEAD

Cell banking may preserve options for potential future use, but it does not guarantee that the cells will be suitable for a specific therapy. Requirements vary, and any future use will depend on the treatment, the condition of the stored cells, and guidance from your healthcare team.

WANT TO LEARN MORE?

Scan the QR codes to learn more about cryopreservation and how cells may be preserved for potential future use from National Cancer Institute

ABOUT US

SCIENCE-BACKED. PATIENT-FOCUSED.

CGT Global facilitates the advancement of cell and gene therapies from research to commercialization, fostering global partnerships and expanding patient access through CGT Clinics nationwide

Founded in 2010, our integrated infrastructure brings together...

A nationwide network of CGT CLINICS

Specialized cell collection and laboratory capabilities

Research, healthcare, and global industry partnerships

By connecting our clinical, laboratory, and industry resources, CGT Global helps coordinate the work involved in evaluating potential therapy pathways from cell collection to engagement with treatment and development partners.

CONNECTING RESOURCES AROUND YOUR CARE

Your potential pathway may involve multiple organizations. CGT Healthcare helps coordinate the clinical, scientific, and regulatory work needed to assess feasibility and clarify what would be required to move forward.

LEARN MORE ABOUT CGT GLOBAL

YOUR EXPERIENCE WITH CGT GLOBAL

PERSONALIZED SUPPORT AT EVERY STEP

Exploring cell and gene therapy options can feel unfamiliar. Our goal is to help you understand the process, the people involved, and the decisions ahead.

COORDINATED AROUND YOU

Your CGT care team works with you, your physician, and relevant clinical and industry partners to coordinate the services included in your care plan. These may include medical review, documentation, testing, collection, and evaluation of potential treatment pathways.

A COMFORTABLE CLINICAL EXPERIENCE

You will be cared for in a welcoming clinical setting by trained professionals who prioritize your comfort and monitor you throughout the collection.

CLEAR COMMUNICATION

We explain what to expect, answer your questions, and keep you informed about what you need to do and what comes next.

SAFETY, QUALITY & PRIVACY

Your health information and collection are handled with care using established clinical and quality procedures designed to protect your safety and privacy.

SUPPORT AFTER COLLECTION

Before you leave, your care team will review potential side effects and recovery instructions. A **24-hour support** line will be available if you have questions or concerns after your collection.

CGT GLOBAL WORKS ALONGSIDE YOUR EXISTING HEALTHCARE TEAM TO SUPPORT YOUR CELL COLLECTION AND CARE JOURNEY.

CGT HEALTHCARE

YOUR THREE-STEP CARE PLAN

An overview of services, potential pathways, and decisions to proceed.

YOUR CARE ROADMAP

Your care plan connects cell collection with evaluation of potential treatment options. The pathway forward depends on your medical needs, available therapies, and clinical and scientific feasibility. Each step requires separate authorization before work begins.

STEP 1 — CELL COLLECTION & STORAGE

Medical review, preparation, apheresis, cell processing, cryopreservation, and storage according to your plan.

STEP 2 — EVALUATION & POTENTIAL TREATMENT

Review your medical needs and investigate available therapies, eligibility, partners, and access requirements. If a feasible pathway is identified, treatment coordination may proceed with separate authorization.

STEP 3 — POTENTIAL NOVEL THERAPY DEVELOPMENT

If no suitable existing therapy is identified, a separate assessment may explore whether developing an individualized therapy is scientifically and clinically feasible.

YOUR PATHWAY IS GUIDED BY YOUR EVALUATION

Your medical needs and evaluation findings will determine which pathway may be appropriate. Before each step begins, we'll review the proposed services, estimated timelines, and costs with you and obtain your authorization to proceed.

STEP 1

LEUKAPHERESIS COLLECTION, CRYOPRESERVATION, AND STORAGE

Step 1 collects and preserves cells for potential use in your care plan. Whether these cells can be used for a particular therapy depends on the selected treatment's requirements and evaluation by the treating team and manufacturing partner.

BEFORE COLLECTION

Before collection, a CGT physician will review the patient's relevant medical history and clinical information to determine whether the patient is appropriate to proceed. CGT will then coordinate patient onboarding, informed consent, scheduling, collection logistics, and the leukapheresis procedure in accordance with applicable CGT clinical procedures.

FOLLOWING COLLECTION

Following collection, CGT will coordinate testing, processing, cryopreservation, labeling, and controlled storage of the collected cells. CGT will maintain appropriate collection, processing, storage, and chain-of-custody records.

Estimated Costs

The estimated collection and cryopreservation cost

$36,000/Per Patient

The estimated annual storage cost per patient is:

$595/Year

SCHEDULING & TIMING

Your collection date will be confirmed after physician review and completion of required screening and preparation. Your CGT team will explain what needs to be completed beforehand and coordinate scheduling and any travel arrangements with you.

> Additional testing, physician services, transportation, specialized processing, or third-party services outside the standard collection package would be identified and approved separately.

STEP 2

APPLY FOR COMPASSIONATE USE OF CELL OR GENE THERAPY

CGT may pursue an individual-patient expanded-access (compassionate-use) pathway for treatment with the applicable cell or gene therapy. CGT will serve as the treatment institution, and a qualified CGT physician will serve as the patient's treating physician.

CARE PLAN SCOPE

The Step 2 care plan may include medical evaluation, engagement with the appropriate therapy developer or manufacturer, coordination of the applicable treatment-access pathway, regulatory and IRB review, treatment planning, institutional readiness, pre-treatment evaluation, therapeutic-product management, treatment administration, patient monitoring, safety management, and required post-treatment clinical and regulatory follow-up.

> Because this is an investigational treatment pathway, the estimates below are intended to establish a reasonable planning budget for the patient and their family. Actual costs will depend on the specific therapy requirements, the authorized treatment plan, the patient's medical needs, third-party charges, and the level of care required before, during, and after treatment.



STEP 2
PART 1

INITIAL MEDICAL EVALUATION AND ELIGIBILITY ASSESSMENT

A qualified CGT Global physician will review the patient's medical history, diagnoses, prior therapies, current condition, laboratory and diagnostic information, and available treatment options. CGT physicians will review the relevant risks and potential benefits and determine whether pursuing a cell or gene therapy treatment pathway is clinically appropriate. This evaluation will also identify any additional records, testing, consultations, or assessments needed to support eligibility and treatment planning.

Estimated Costs

$5,000–$10,000



STEP 2
PART 2

MANUFACTURER, REGULATORY, AND TREATMENT COORDINATION

If the physician determines that a cell or gene therapy pathway may be appropriate, CGT will coordinate the next-stage process. Depending on the therapy and access pathway, this may include engagement with the therapy developer or manufacturer, confirmation of product availability, coordination of applicable regulatory and IRB submissions, treatment planning, and any required cell collection or other protocol-specific preparation.

Coordination cost

Estimated CGT Healthcare coordination cost:

$10,000

If the required approvals and authorizations are obtained, the treatment program may include product sourcing or manufacturing, logistics, pre-treatment evaluation and conditioning, therapeutic product receipt and management, treatment administration, acute monitoring, safety management, and required post treatment follow up. Final requirements and pricing will depend on the selected therapy, treatment plan, site-of-care requirements, and the patient's clinical needs.

Treatment estimate

$300,000 - $1,500,000/Per Patient

> This estimate is for planning purposes only and may include significant third-party charges. A detailed budget will be developed once the manufacturer, treatment plan, site-of-care requirements, and regulatory pathways are finalized.

STEP 3

PERSONALIZED GENE-EDITING THERAPY

Step 3 would explore whether the development of a personalized gene-editing therapy is scientifically and clinically feasible for an individual patient. Because each patient's condition and underlying biology are unique, every potential treatment would require an individualized genomic, clinical, and regulatory assessment.

The path would be as follows:

1. Patient genomic sequencing
2. Identify pathogenic variant
3. Validate disease mechanism
4. Design a patient-specific gene-editing strategy
5. Manufacture the therapeutic product
6. Preclinical validation
7. Regulatory authorization
8. Individual treatment

Comprehensive genomic sequencing and analysis will be conducted to identify a potentially actionable pathogenic variant and to evaluate whether the identified variant is scientifically linked to the disease mechanism. Based on those findings, an appropriate gene-editing strategy and therapeutic modality will be selected and designed.

LEARN MORE ABOUT PERSONALIZED THERAPY DEVELOPMENT

Scan to explore how personalized therapies are developed around the biology and clinical needs of an individual patient.

STEP 3

PERSONALIZED GENE-EDITING THERAPY

The program may also involve engagement with specialized academic, biotechnology, manufacturing, and regulatory partners, as well as preclinical analytical, functional, and safety studies appropriate to the proposed therapy. CGT Global will coordinate development of the applicable regulatory strategy, which may include an individual-patient IND or another FDA-authorized pathway, depending on the therapy and individual circumstances.

Development estimate

Preliminary therapy-development estimate:

$10,000,000 - $15,000,000 per gene-editing care plan

If the care plan advances to clinical use, the scope includes manufacturing, release testing, treatment planning, administration, and post-treatment monitoring.

Treatment estimate

Preliminary treatment estimate after development:

$700,000 - $1,500,000 per patient

These figures are high-level planning estimates only. Actual costs may vary materially based on the genetic target, therapeutic modality, preclinical requirements, manufacturing approach, regulatory requirements, number of patients, and third-party partner costs.

IN SUMMARY

Each step will require separate written authorization before initiation.

A retainer and/or payment schedule will be established and mutually agreed upon before each phase begins.

CGT Global will provide monthly invoices and progress updates for active phases.

Any material expansion of scope or budget will be discussed with and approved by the patient or their authorized representative before additional work is undertaken.

Additional costs, including travel, direct-billed services, and approved pass-through expenses, will be billed separately.

Phase	Objective	Estimated Cost	Key Dependency
1	Leukapheresis, cryopreservation, storage	$36,000/patient + $595/year storage	Clinical clearance for collection
2	Cell or gene therapy evaluation, access, and treatment coordination	$15,000-$20,000 initial coordination; therapy budget est. $700,000 - $1.5M	Physician determination, manufacturer agreement, FDA authorization
3	Personalized gene-editing care plan	$10M-$15M development estimate; treatment est. $700,000 - $1.5M/patient	Actionable variant, scientific feasibility, regulatory pathway, manufacturing partner

Estimated timelines will be reviewed before each step begins and will depend on clinical requirements, partner availability, and applicable approvals.

"Every patient's journey is different. Progress begins by creating a path as individual as the person it serves."

- Cate Spears. CEO & Founder



CGT HEALTHCARE

CGT Global Headquarters
100 Sandhill Road,
Reno, NV, 89521

info@cgthealthcare.com

877-900-7836

California Clinic & Laboratory
1733 Creekside Drive,
Folsom, CA, 95630

Massachusetts Clinic & Laboratory
1230 Soldiers Field Rd,
Boston, MA, 02135

Pennsylvania Clinic & Laboratory
325 W. Germantown Pike,
East Norriton, PA, 19403